Skip to main content

Zoetis Inc. stock price and financials

  • ZTS · NYSE
  • Pharmaceuticals
  • S&P 500
$83.82+1.04%Close 13 Nov 2026
EV / EBITDA
10.74
Beta · 1 year
0.61
Return · 1 year
−30.9%
52-week range$68.77 — $132.49

Share price close 16 Nov 2026

+6.8%1 monthHigh $89.20Low $77.80
$75$80$85$90Q3 FY2026 report filed 5 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+12.8%6 monthsHigh $89.20Low $69.10
$60$70$80$90Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 5 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
−33.4%year to dateHigh $131.10Low $69.10
$60$80$100$120$140Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 5 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−30.7%1 yearHigh $131.10Low $69.10
$60$80$100$120$140Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 5 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
−52.0%3 yearsHigh $200.09Low $69.10
$50$100$150$200$250Q4 FY2023 report filed 13 Feb 2024Q1 FY2024 report filed 2 May 2024Q2 FY2024 report filed 6 Aug 2024Q3 FY2024 report filed 4 Nov 2024Q4 FY2024 report filed 13 Feb 2025Q1 FY2025 report filed 6 May 2025Q2 FY2025 report filed 5 Aug 2025Q3 FY2025 report filed 4 Nov 2025Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 7 May 2026Q2 FY2026 report filed 6 Aug 2026Q3 FY2026 report filed 5 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+67.9%10 yearsHigh $244.03Low $49.10
$0$50$100$150$200$250Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Zoetis Inc. reported revenue of $9.47 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 2.3% from fiscal 2024. Net income was $2.67 billion and diluted earnings per share $6.02.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.39 billion, down 1.3% from a year earlier.

Figures from Zoetis Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Nov 2026.

Revenue FY2025
$9.47B+2.3%
Net income
$2.67B+7.5%
Diluted EPS
$6.02+10.1%
Gross margin
71.8%+1.2 pts
Free cash flow
$2.28B−0.7%
Net debt
$6.84B+42.3%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$2B$4B$6B$8B$10BRevenue, FY16: $4.89BNet income, FY16: $821MFY16Revenue, FY17: $5.31BNet income, FY17: $864MFY17Revenue, FY18: $5.83BNet income, FY18: $1.43BFY18Revenue, FY19: $6.26BNet income, FY19: $1.5BFY19Revenue, FY20: $6.67BNet income, FY20: $1.64BFY20Revenue, FY21: $7.78BNet income, FY21: $2.04BFY21Revenue, FY22: $8.08BNet income, FY22: $2.11BFY22Revenue, FY23: $8.54BNet income, FY23: $2.34BFY23Revenue, FY24: $9.26BNet income, FY24: $2.49BFY24Revenue, FY25: $9.47BNet income, FY25: $2.67BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 5 Nov 2026 · Full results →

Revenue
$2.39B−1.3% on a year
Gross margin
70.8%−0.4 pts on a year
Operating income
$863.0M−7.4% on a year
Net income
$591.0M−18.0% on a year
Diluted EPS
$1.44−11.7% on a year
Free cash flow
$717.0M−10.2% on a year

Comparable companies All of Health Care →

Zoetis Inc. beside the other S&P 500 members in Pharmaceuticals, by market value.

Zoetis Inc. and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
ZoetisZTS—+1.0%−30.9%———
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
Bristol Myers SquibbBMY$128.5B+1.8%+29.2%+4.2%18.5%13.9
Merck & Co.MRK—+0.6%+61.6%———
PfizerPFE—+0.2%+11.7%———
ViatrisVTRS—+0.7%+89.1%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%71.8%37.5%28.2%FY16FY19FY22FY25

Zoetis Inc. revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By region

Zoetis Inc. revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
U.S.$4.04B$4.31B+6.7%$4.55B+5.6%$5.07B+11.4%$5.10B+0.5%
International$3.65B$3.68B+0.8%$3.91B+6.2%$4.10B+4.9%$4.25B+3.7%
Total revenue$7.78B$8.08B$8.54B$9.26B$9.47B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Zoetis Inc. income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$4.89B$5.31B$5.83B$6.26B$6.67B$7.78B$8.08B$8.54B$9.26B$9.47B
Revenue growth+2.6%+8.6%+9.8%+7.5%+6.6%+16.5%+3.9%+5.7%+8.3%+2.3%
Gross profit$3.22B$3.53B$3.91B$4.27B$4.62B$5.47B$5.63B$5.98B$6.54B$6.80B
Operating income$1.39B$1.71B$1.81B$1.97B$2.24B$2.76B$2.92B$3.02B$3.34B$3.55B
Net income$821.0M$864.0M$1.43B$1.50B$1.64B$2.04B$2.11B$2.34B$2.49B$2.67B
Diluted EPS$1.65$1.75$2.93$3.11$3.42$4.27$4.49$5.07$5.47$6.02
Gross margin65.9%66.6%67.2%68.2%69.2%70.4%69.6%70.0%70.6%71.8%
Operating margin28.5%32.1%31.1%31.4%33.6%35.5%36.1%35.3%36.1%37.5%
Net margin16.8%16.3%24.5%24.0%24.5%26.2%26.2%27.4%26.9%28.2%

Cash flow

Zoetis Inc. cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$713.0M$1.35B$1.79B$1.79B$2.13B$2.21B$1.91B$2.35B$2.95B$2.90B
Capital expenditure$216.0M$224.0M$338.0M$460.0M$453.0M$477.0M$586.0M$732.0M$655.0M$621.0M
Free cash flow$497.0M$1.12B$1.45B$1.33B$1.67B$1.74B$1.33B$1.62B$2.30B$2.28B

Balance sheet and shares

Zoetis Inc. balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$727.0M$1.56B$1.60B$1.93B$3.60B$3.48B$3.58B$2.04B$1.99B$2.45B
Total debt$4.47B$4.95B$6.65B$6.65B$7.40B$6.78B$8.13B$6.80B$6.79B$9.29B
Shareholders' equity$1.49B$1.77B$2.19B$2.71B$3.77B$4.54B$4.41B$5.00B$4.77B$3.42B
Diluted shares498M493M487M482M479M477M470M462M455M444M
Dividends per share$0.39$0.44$0.54$0.69$0.85$1.07$1.35$1.56$1.80$2.03

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Zoetis Inc. quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.32B$2.20B$2.47B$2.42B$2.37B$2.26B$2.47B$2.39B
Revenue, year on year+4.7%+0.4%+4.8%+1.4%+2.4%+2.9%−0.2%−1.3%
Gross margin69.5%71.9%73.2%71.2%71.0%71.7%72.7%70.8%
Operating income$763.0M$812.0M$967.0M$932.0M$835.0M$800.0M$922.0M$863.0M
Net income$581.0M$602.0M$726.0M$721.0M$624.0M$601.0M$691.0M$591.0M
Diluted EPS$1.29$1.34$1.63$1.63$1.42$1.42$1.65$1.44
Free cash flow$689.0M$337.0M$459.0M$798.0M$689.0M$291.0M$538.0M$717.0M

Operating KPIs

The operating figures Zoetis Inc. reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Zoetis Inc. operating KPIs
KPILatestPeriodChange on a yearRecent periods
Dogs and Cats revenue$1.5Bquarter to 30 Sep 2026down 5.6%
Livestock revenue$797.0Mquarter to 30 Sep 2026up 6.8%
Parasiticides revenue$576.0Mquarter to 30 Sep 2026up 2.7%
Vaccines revenue$540.0Mquarter to 30 Sep 2026up 5.5%
Cattle revenue$439.0Mquarter to 30 Sep 2026up 5.8%
Dermatology revenue$398.0Mquarter to 30 Sep 2026down 15.7%
Anti-infectives revenue$282.0Mquarter to 30 Sep 2026down 1.7%
Pain and sedation revenue$200.0Mquarter to 30 Sep 2026unchanged
Animal health diagnostics revenue$128.0Mquarter to 30 Sep 2026up 14.3%
Swine revenue$120.0Mquarter to 30 Sep 2026up 3.4%
Poultry revenue$108.0Mquarter to 30 Sep 2026up 1.9%
Fish revenue$98.0Mquarter to 30 Sep 2026up 22.5%
Horses revenue$73.0Mquarter to 30 Sep 2026up 5.8%
Sheep and other revenue$32.0Mquarter to 30 Sep 2026up 10.3%
Contract manufacturing & human health revenue$29.0Mquarter to 30 Sep 2026up 11.5%
Medicated feed additives revenue$12.0Mquarter to 31 Dec 2025down 76.5%
Companion Animal revenue$585.0Mquarter to 30 Sep 2026up 0.7%
U.S. revenue$1.2Bquarter to 30 Sep 2026down 5.7%
International revenue$1.1Bquarter to 30 Sep 2026up 3.9%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Zoetis Inc.'s revenue in fiscal 2025?

$9.47 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Zoetis Inc.'s net income in fiscal 2025?

$2.67 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Zoetis Inc.'s diluted earnings per share in fiscal 2025?

$6.02 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Zoetis Inc.'s gross margin?

71.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Zoetis Inc.'s operating margin?

37.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Zoetis Inc. generate in fiscal 2025?

$2.28 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Zoetis Inc.'s revenue come from?

In fiscal 2025, by product: Livestock $2.76B (29%), Vaccines $1.96B (21%), Anti-infectives $1.04B (11%), Pain and sedation $840.0M (8.9%), out of $9.47B in all, as stated in its annual report.

In the terminal

Twenty years of Zoetis Inc.'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans